<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02493335</url>
  </required_header>
  <id_info>
    <org_study_id>BUL-2/EER</org_study_id>
    <secondary_id>2014-001485-99</secondary_id>
    <nct_id>NCT02493335</nct_id>
  </id_info>
  <brief_title>Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis</brief_title>
  <acronym>EOS-2</acronym>
  <official_title>Double-blind, Randomized, Placebo-controlled, Phase III Study on the Efficacy and Tolerability of a 48-week Treatment With Two Different Doses of Budesonide Effervescent Tablets vs. Placebo for Maintenance of Clinico-pathological Remission in Adult Patients With Eosinophilic Esophagitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Falk Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Falk Pharma GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to prove the superiority of a 48-weeks treatment with budesonide
      orodispersible tablets versus placebo for the maintenance of clinico-pathological remission
      in patients with eosinophilic esophagitis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2016</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of patients free of treatment failure after 48 weeks of treatment.</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with histological relapse</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of patients with clinical relapse</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Eosinophilic Esophagitis</condition>
  <arm_group>
    <arm_group_label>Budesonide 0.5mg orodispersible tablet twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonide 0.5mg orodispersible tablet twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Budesonide 1mg orodispersible tablet twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonide 1mg orodispersible tablet twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo orodispersible tablet twice daily</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo orodispersible tablet twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide 0.5mg orodispersible tablet twice daily</intervention_name>
    <arm_group_label>Budesonide 0.5mg orodispersible tablet twice daily</arm_group_label>
    <other_name>BUL 0.5mg BID</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Budesonide 1mg orodispersible tablet twice daily</intervention_name>
    <arm_group_label>Budesonide 1mg orodispersible tablet twice daily</arm_group_label>
    <other_name>BUL 1mg BID</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo orodispersible tablet twice daily</intervention_name>
    <arm_group_label>Placebo orodispersible tablet twice daily</arm_group_label>
    <other_name>Placebo BID</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent,

          -  Male or female patients, 18 to 75 years of age,

          -  Confirmed clinico-pathological diagnosis of eosinophilic esophagitis (EoE) according
             to established diagnostic criteria

          -  Clinico-pathological remission of EoE,

          -  A documented trial with proton pump inhibitors (PPIs) in order to rule out
             PPI-responsive esophageal eosinophilia,

          -  Negative pregnancy test in females of childbearing potential at baseline visit.

        Exclusion Criteria:

          -  Clinical and endoscopic signs of gastroesophageal reflux disease (GERD),

          -  History of abnormal results in case of an optionally performed pH-monitoring of the
             distal esophagus,

          -  Patients with PPI-responsive esophageal eosinophilia

          -  Achalasia, scleroderma esophagus, or systemic sclerosis,

          -  Other clinically evident causes than EoE for esophageal eosinophilia,

          -  Any concomitant esophageal disease and relevant gastro-intestinal disease (celiac
             disease, inflammatory bowel disease, oropharyngeal or esophageal bacterial, viral, or
             fungal infection [candida esophagitis]),

          -  Any relevant systemic disease (e.g., AIDS, active tuberculosis),

          -  If careful medical monitoring is not ensured: cardiovascular disease, diabetes
             mellitus, osteoporosis, active peptic ulcer disease, glaucoma, cataract, or infection,

          -  Liver cirrhosis or portal hypertension,

          -  History of cancer in the last five years,

          -  History of esophageal surgery at any time or of esophageal dilation procedures within
             the last 8 weeks prior to screening visit,

          -  Upper gastrointestinal bleeding within 8 weeks prior to baseline visit,

          -  Existing or intended pregnancy or breast-feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph Mueller, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Dr. Falk Pharma GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ralph MÃ¼ller, PhD</last_name>
    <phone>+49-761-1514</phone>
    <phone_ext>0</phone_ext>
    <email>ralph.mueller@drfalkpharma.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Roland Greinwald, PhD</last_name>
    <phone>+49-761-1514</phone>
    <phone_ext>0</phone_ext>
    <email>roland.greinwald@drfalkpharma.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Center for Digestive Diseases Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20249</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Miehlke, Prof. Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2015</study_first_submitted>
  <study_first_submitted_qc>July 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2015</study_first_posted>
  <last_update_submitted>February 3, 2017</last_update_submitted>
  <last_update_submitted_qc>February 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Eosinophilic Esophagitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

